5AM Ventures’ Post

5AM Ventures reposted this

View organization page for Dianthus Therapeutics, Inc., graphic
Dianthus Therapeutics, Inc.

5,229 followers

We are excited to announce we received FDA clearance of our Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN). Top-line results are expected to be available in the second half of 2026. Learn more: https://lnkd.in/ggZZeSfZ #biotech #MMN

  • No alternative text description for this image
Archie Stone, PhD

Vice President of Product Development @ Aurinia Pharmaceuticals Inc. | Medical Affairs

4mo

Congrats Sim. Exciting times ahead for you and the Dianthus team.

Like
Reply
2 Reactions
Anna Pavlova-Wolf, PhD

Medical Affairs Strategy, National Director of Field Medical Affairs Founder, LaunchMedUSA

4mo

Sim, how exciting, congratulations and successful Phase 3!

Like
Reply
1 Reaction
Laura Veasey

Enhance Patient Safety | Pharma | Healthcare | Multi-Cultural Competence | System & Process Implementation | Data Quality | Cross-Functional Collaboration | Unmet Medical Need | Compassionate | Engaged | Value Integrity

4mo

Well done Sim and team!

Like
Reply
1 Reaction
Bonni Scepkowski

4mo

Fantastic news, congratulations

Like
Reply
Kym Bean

Specialty Healthcare Sales

4mo

Awesome news! Congratulations!

Like
Reply
1 Reaction
Bilal Bham

I am a registered Diverse Supplier helping biotech, pharma, and medical devices companies bring their products to market and patients through regulatory submissions and medical communications.

4mo

Congratulations!

Like
Reply
1 Reaction
Nicole Slawny

Midwest Field Medical Director

4mo

Congratulations!

Like
Reply
1 Reaction
See more comments

To view or add a comment, sign in

More Relevant Posts

5AM Ventures

19,839 followers

View Profile

Explore topics